Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 September;52(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 September;52(3):215-21

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 September;52(3):215-21

AN OVERVIEW OF THE RADIOPHARMACOLOGY FIELD TO DATE 

 REVIEWS

Small animal PET in preclinical studies: opportunities and challenges

Riemann B., Schäfers K. P., Schober O., Schäfers M.

Department of Nuclear Medicine University Hospital, Münster, Germany

The process of drug and molecular imaging development is strongly influenced by the revolution of non-invasive imaging techniques. Small animal positron emission tomography (PET) has the potential to accelerate and streamline drug and molecular imaging discovery and development by preselection of suitable candidate molecules. Due to its significantly improved spatial resolution and its quantitative nature, compared to other techniques small animal PET can be employed to bridge the in vitro, through to preclinical and clinical imaging in humans.

language: English


FULL TEXT  REPRINTS

top of page